2022 the Japanese Society of Medical Oncology Annual Meeting

Presentation information

Print

Oral Session

[O13] Oral Session 13　Lung Cancer / Thoracic Cancer 3（Rare gene alterations）
【E】

Sat. Feb 19, 2022 8:20 AM - 9:50 AM Room 1 (Main Hall, 1F, Kyoto International Conference Center)

Chair：Satoshi Oizumi（Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center），Haruyasu Murakami（Chemotherapy Center/Division of Thoracic Oncology, Shizuoka Cancer Center）
Discussant：Takehito Shukuya（Department of Respiratory Medicine, Juntendo University）

[O13-1] Phase II study of brigatinib in ROS1 positive non-small cell lung cancer patients previously treated with crizotinib.

○Yasushi Goto1, Seiji Niho2, Haruko Daga3, Sakakibara-Konishi Sakakibara-Konishi4, Hiroshi Tanaka5, Kadoaki Ohashi6, Ryo Toyozawa7, Masahiro Kotani8, Toshiaki Takahashi9, Yoshihiro Hattori10, Masahiro Morise11, Takaya Ikeda2, Shingo Matsumoto2, Kiyotaka Yoh2, Shogo Nomura12, Koichi Goto2 (1.Department of Thoracic Oncology, National Cancer Center Hospital, 2.National Cancer Center Hospital East, 3.Osaka City General Hospital, 4.Hokkaido University Hospital, 5.Niigata Cancer Center Hospital, 6.Okayama University Hospital, 7.National Hospital Organization Kyushu Cancer Center, 8.Tottori University, 9.Shizuoka Cancer Center, 10.Hyogo Cancer Center, 11.Nagoya University Graduate School of Medicine, 12.The University of Tokyo)

Abstract password authentication.
The password can be found on page 27 of the program book.

Password